CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		122 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Cash flows from operating activities
Net loss	$ (4,177,482)	$ (2,373,999)	$ (113,789,102)
Adjustments to reconcile net loss to net cash used in operating activities
Stock payable for acquired research and development			112,440
Stock issued for acquired research and development			26,286,589
Stock issued for services			2,061,743
Stock issued for debt in excess of principal			109,070
Amortization of discount on notes payable due to warrants and beneficial conversion feature	1,237,662		8,094,392
Loss/(Gain) on extinguishment of debt			(1,612,440)
Depreciation	78,311	67,355	1,728,469
Amortization of debt financing costs	52,939		635,956
Option expense	411,187	205,420	16,677,120
Loss/(Gain) on derivative instruments			(1,941,826)
Loss on disposition of fixed assets			513,345
Changes in:
Deferred revenue	4,779,900		4,779,900
Other current assets	(115,589)	(880,983)	(1,268,642)
Accounts payable - third parties and related parties	418,562	1,022,532	257,911
Accrued expenses	457,240	(225,743)	1,062,478
Other assets	(104,027)		(104,027)
Net cash provided by (used in) operating activities	3,038,703	(2,185,418)	(56,396,624)
Cash flows from investing activities
Purchase of property & equipment	(2,598)	(245,841)	(2,224,797)
Restricted cash	500,000		(500,000)
Net cash provided by (used in) investing activities	497,402	(245,841)	(2,724,797)
Cash flows from financing activities
Common stock and warrants sold for cash, net of offering costs	3,623,738		53,077,535
Common stock repurchased and canceled			(325)
Proceeds from exercise of warrants and options			1,248,588
Proceeds from third party debt	550,000		13,288,184
Proceeds from related party debt	100,000		730,000
Deferred financing and offering costs	(17,511)		(527,003)
Repayment on related party notes payable	(100,000)		(100,000)
Repayments on notes payable	(450,000)		(761,222)
Net cash provided by financing activities	3,706,227		66,955,757
Net change in cash and cash equivalents	7,242,332	(2,431,259)	7,834,336
Cash and cash equivalents at beginning of period	592,004	7,109,215
Cash and cash equivalents at end of period	7,834,336	4,677,956	7,834,336
Cash paid for:
Income tax
Interest	18,647	487	173,756
NON-CASH TRANSACTIONS
Issuance of common stock to Sportan shareholders			147,733
Issuance of common stock for accrued interest			789,287
Issuance of warrants to placement agent			37,453
Conversion of notes payable to common stock	1,000,000		8,709,980
Conversion of accrued liabilities to common stock			197,176
Conversion of accounts payable to note payable			93,364
Discount on convertible notes relating to:
Warrants	195,969		6,170,341
Beneficial conversion feature	141,829		3,444,982
Stock attached to notes			1,287,440
Fair value of derivative instrument			4,680,220
Derivative reclassified to equity			2,349,266
Unpaid additions to property and equipment		182,952
Amortization of deferred offering costs to paid-in capital	$ 45,450		$ 92,789
Shares issued as deferred offering costs	1,234		150,365